Hepatocellular carcinoma
Conditions
Interventions
Observation group:None
Sponsors
The People's Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years, no gender restriction; 2.Histologically or radiologically confirmed diagnosis of hepatocellular carcinoma (HCC), meeting the clinical diagnostic criteria for liver cancer; 3.BCLC stage A, B, C (only for portal vein branch invasion VP1/2 level, main trunk not completely occluded); 4.ECOG 0-2; 5.Child Pugh A or B (<= 7 points); 6.Received at least one DEB-TACE treatment, and DEB-TACE is one of the main treatment methods (can be combined with other local or systematic therapies); 7.Able to understand and cooperate to complete the PRO scale filling; 8.Able to accept the follow-up arrangements set by this study, with the willingness and ability to complete the entire research process; 9.Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Severe liver dysfunction or decompensation (Child-Pugh classification C or significant decompensation symptoms such as persistent ascites, hepatic encephalopathy, recurrent bleeding, etc.), renal insufficiency (eGFR < 30 mL/min/1.73m² or requiring long-term dialysis treatment), cardiovascular diseases (serious cardiovascular events within the last 6 months, such as acute myocardial infarction, acute heart failure, severe arrhythmias, uncontrolled hypertension, etc.), hematological diseases (active bleeding disorders, severe anemia (Hb < 8 g/dL), leukopenia (WBC < 2.0×10^?/L) or thrombocytopenia (PLT < 50×10^?/L)), or immune system diseases (active systemic lupus erythematosus, rheumatoid arthritis, immunosuppressive state after organ transplantation, HIV infection (CD4 < 200/µL), etc.); 2.Presence of other primary malignant tumors (excluding liver metastatic cancer) or end-stage liver failure during treatment; 3.History of clear mental, cognitive, or neurological dysfunction, unable to complete questionnaire assessment independently; 4.Expected survival of less than 3 months or clinical judgment that follow-up cannot be completed; 5.Any other conditions deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of patient-reported outcomes;Overall survival, OS; | — |
Countries
China
Contacts
Public ContactLei Yu
The People's Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed